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Article
Brd4-Brd2 isoform switching coordinates
pluripotent exit and Smad2-dependent
lineage specification
Rosalia Fernandez-Alonso1, Lindsay Davidson2, Jens Hukelmann3, Michael Zengerle4, Alan R Prescott3,
Angus Lamond3 , Alessio Ciulli4, Gopal P Sapkota1 & Greg M Findlay1,*
Abstract
Pluripotent stem cells (PSCs) hold great clinical potential, as they
possess the capacity to differentiate into fully specialised tissues
such as pancreas, liver, neurons and cardiac muscle. However, the
molecular mechanisms that coordinate pluripotent exit with
lineage specification remain poorly understood. To address this
question, we perform a small molecule screen to systematically
identify novel regulators of the Smad2 signalling network, a key
determinant of PSC fate. We reveal an essential function for BET
family bromodomain proteins in Smad2 activation, distinct from
the role of Brd4 in pluripotency maintenance. Mechanistically, BET
proteins specifically engage Nodal gene regulatory elements
(NREs) to promote Nodal signalling and Smad2 developmental
responses. In pluripotent cells, Brd2-Brd4 occupy NREs, but only
Brd4 is required for pluripotency gene expression. Brd4 downregu-
lation facilitates pluripotent exit and drives enhanced Brd2 NRE
occupancy, thereby unveiling a specific function for Brd2 in dif-
ferentiative Nodal-Smad2 signalling. Therefore, distinct BET func-
tionalities and Brd4-Brd2 isoform switching at NREs coordinate
pluripotent exit with lineage specification.
Keywords BET Bromodomain; differentiation; embryonic stem cell;
Nodal-Smad2 signalling; Pluripotency
Subject Categories Signal Transduction; Stem Cells
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Introduction
Embryonic/pluripotent stem cells (ESCs/PSCs) have the develop-
mental capacity to differentiate into any cell type within the adult
body, including terminally differentiated tissues such as pancreas,
liver, neurons and cardiac muscle [1]. Thus, directed differentiation
is of significant clinical interest due to potential applications in
regenerative therapeutics. Although many insights into the signal-
ling pathways controlling differentiation have been gleaned from
developmental genetics and embryology [2], the molecular events
which coordinate pluripotent exit with developmental progression
are poorly understood.
Transforming growth factor (TGF)-b signalling plays a promi-
nent role both in maintaining pluripotency and in mesendoderm
(ME) specification [3–5], which is a developmentally and thera-
peutically significant population [2]. The TGFb superfamily
consists of TGFb isoforms and Activin/Nodal ligands, which selec-
tively engage TGFbII receptors. This leads to TGFbI receptor
activation, Smad2/3 recruitment and phosphorylation, and Smad2/
3-dependent gene expression in complex with Smad4 [3–5]. In
PSCs, autocrine Nodal activates Smad2 signalling [6] to maintain
expression of pluripotency factors [7,8]. In differentiating cells,
Nodal-Smad2 induces ME-specific genes [9,10] and reinforces ME
fate selection by suppressing neuroectoderm (NE) genes [11,12]
(Fig 1A). However, in contrast to our detailed understanding of
the core Nodal-Smad2 pathway and transcriptional targets, we
remain poorly informed about the molecular mechanisms by
which Smad2 signalling is established and maintained in diverse
developmental contexts.
Here, we use a library of potent and selective small molecule
inhibitors to uncover the regulatory network surrounding the
Nodal-Smad2 pathway in differentiating PSCs. This approach identi-
fies bromodomain and extra-terminal (BET) proteins as unantici-
pated regulators of Nodal-Smad2 signalling, distinct from the role of
Brd4 in pluripotency maintenance. We find that BET family
members Brd2 and Brd4 directly engage Nodal gene regulatory
elements (NREs) to drive autocrine Nodal expression. Using quanti-
tative proteomics to explore BET family expression dynamics during
differentiation, we show that Brd4 suppression facilitates pluripo-
tent exit and drives increased Brd2 recruitment to NREs. Brd2
thereby selectively governs Smad2 pathway activation in differenti-
ating cells and is required for ME differentiation. Our data uncover a
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Figure 1.
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BET family isoform switch and distinct BET family functionalities,
which together enable coordinated pluripotent exit with Nodal-
Smad2 dependent lineage specification.
Results
A screen for modifiers of Nodal-Smad2 pathway activity during
mESC differentiation
In order to elucidate the extended regulatory network surrounding
the core Nodal-Smad2 pathway in differentiating PSCs, we
employed mouse ESCs (mESCs) maintained in Mek1/2 (PD0325901)
and Gsk3 (CHIR99021) inhibitors, referred to as “2i” [13]. Upon 2i
release [14], naı¨ve ESCs (Klf4) undergo differentiation towards
epiblast (Fgf5), followed by lineage specification of NE (Nestin) and
ME (Brachyury; Fig 1B [15]). ME differentiation requires Smad2
pathway activation [16,17], as Brachyury induction is suppressed
by treatment with the TGFbI receptor inhibitor SB505124 [18]
(Fig 1C). Brachyury is also regulated by Fgf-Mek1/2 and Wnt signal-
ling in the expected manner, as the Mek1/2 inhibitor PD0325901
suppresses, whilst the Gsk3 inhibitor CHIR99021 promotes
Brachyury expression (Fig 1C). Each inhibitor appropriately
suppresses signalling pathway output (Fig 1D).
We therefore exploited Brachyury induction as a biological assay
for Nodal-Smad2 signalling in differentiating mESCs. A screen of
105 potent and selective tool compounds identifies several small
molecules which potently suppress Brachyury induction (Fig 1E,
see also Appendix Table S1). In this cohort are TGFbI receptor
inhibitors A-83-01 and LY364947, the Nedd8 activating enzyme inhi-
bitor MLN4924, the p90 Ribosomal S6 Kinase (RSK) inhibitor BI-
D1870 and the bromodomain and extra-terminal (BET) inhibitor
JQ1.
BET bromodomain activity is required for Nodal-Smad2 signalling
in differentiating mESCs
Initially, we investigated whether hits identified in our screen
directly affect Nodal-Smad2 signalling. MLN4924 suppresses expres-
sion of multiple lineage markers (Fig EV1A), whilst a structurally
distinct p90 RSK inhibitor SL0101 does not inhibit Brachyury expres-
sion (Fig EV1B), suggesting that MLN4924 and BI-D1870 have non-
specific effects in differentiating mESCs. However, JQ1 specifically
abolishes Smad2 phosphorylation without inhibiting Fgf-Mek1/2 or
Wnt signalling (Fig 2A), demonstrating that the Nodal-Smad2
pathway is a functional target of BET activity in differentiating
mESCs. We corroborate this observation using other BET inhibitors
including IBET and the structurally unrelated IBET-151 and PFI-1
(Fig 2B) [19,20]. In contrast, RVX-208, a specific inhibitor of the
second BET bromodomain [21], does not significantly suppress
Smad2 phosphorylation (Fig 2B).
We asked whether diverse BET inhibitors consistently block
Brachyury induction in differentiating mESC. Suppression of
Brachyury by BET inhibitors closely correlates with inhibition of
Smad2 phosphorylation (Fig 2C). We also confirm that JQ1
suppresses expression of Nanog, a known target gene (Fig EV1C)
and Brachyury protein (Fig EV1D). Furthermore, JQ1 inhibits direct
Smad2 transcriptional targets and ME markers Mixl and Gsc
(Fig EV1E) and strongly promotes Sox1+ NE lineage selection in a
manner similar to TGFbI receptor inhibition (Fig 2D) [22]. In
contrast, JQ1 does not suppress Smad1 phosphorylation, a specific
readout of BMP signalling (Fig EV1F), indicating that BET inhibition
specifically blocks the TGFb-Smad2 axis of the TGFb/BMP signalling
network. Taken together, our data provide substantial evidence that
BET inhibitors block Nodal-Smad2 dependent signalling during
mESC differentiation.
BET function patterns autocrine Nodal expression to underpin
Smad2 pathway activation
Initially, we speculated that BET inhibitors suppress Nodal-Smad2
signalling by inhibiting a kinase. However, JQ1 does not inhibit
> 140 kinases, including the TGFbI receptor Alk5 [23,24]. Consis-
tent with this finding, BET inhibition suppresses Smad2 phospho-
rylation only after 48 h (Fig EV2A), suggesting that BET proteins
control Nodal-Smad2 signalling via a transcriptional mechanism.
In order to identify BET-dependent transcripts in the TGFb and
Wnt signalling networks, we interrogated published RNAseq data
from PSCs (Gene Expression Omnibus GSE60171) [22]. This
analysis indicates that NODAL and INHBE ligands and the
Smad2-dependent negative feedback regulator LEFTY2 are
repressed following BET inhibition (Fig 3A), suggesting a poten-
tial mechanism by which BET proteins function in Nodal-Smad2
signalling.
To test this hypothesis, we conducted a targeted mRNA expres-
sion analysis of TGFb signalling components in mESCs following 2i
release (Fig 3B). As expected, Smad2 transcriptional targets
Brachyury, Mixl and Lefty1/2 are potently suppressed by JQ1 [25].
Strikingly, JQ1 treatment also suppresses expression of
Activin/Inhibin and Nodal type TGFb ligands, whilst TGFb family
◀ Figure 1. A chemical screen to identify novel players in the Smad2 pathway.A Schematic representation of mESC differentiation towards mesendoderm (ME) and neuroectoderm (NE) fates. Nodal-Smad2 signalling controls ME specification.
B Klf4, Fgf5, Nestin and Brachyury mRNA levels in mESCs differentiating upon 2i release were quantified by qRT–PCR and normalised to mRNA levels in 2i mESCs. Data
are presented as mean  SEM of technical replicates from a representative experiment; similar results were observed in three independent experiments (n = 3).
C mESCs differentiating upon 2i release for 4 days were treated with PD0325901 (MEK1/2 inhibitor; 1 lM), CHIR99021 (GSK3 inhibitor; 3 lM) and SB505124 (TGFbRI
inhibitor; 3 lM) on either day 1, 2 or 3 as indicated. mRNA levels of Klf4 and Brachyury were quantified by qRT–PCR and normalised to DMSO control. Data are
presented as mean  SEM of technical replicates from three independent experiments (n = 3).
D mESCs differentiating upon 2i release for 1.5 days were treated with 1 lM PD0325901, 3 lM CHIR99021 or 3 lM SB505124 for a further 2.5 days. Smad2 Ser465/467,
b-catenin Ser33/37/41 and Erk1/2 Thr202/Tyr204 phosphorylation and total Erk1/2 or b-catenin were determined by immunoblotting (n = 3).
E Screen of Brachyury mRNA levels following mESC differentiation with inhibitors (1 lM; JQ1 100 nM) added for the final 2.5 days. Data are presented as mean of
technical replicates. Small molecules and primary targets which robustly inhibit Brachyury induction are highlighted.
Source data are available online for this figure.
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receptor/co-receptor expression is only modestly altered or
increased by JQ1 (Fig 3B). Selective suppression of Activin/Nodal
ligands may therefore underpin Nodal-Smad2 inhibition by JQ1.
Nodal is prominently expressed during early development [26] and
in differentiating mESCs (Fig 3C), suggesting that BET proteins drive
Nodal expression and resulting Smad2 signalling in differentiating
mESCs.
In order to determine whether Activin/Nodal ligand expression is
the key BET-dependent step in the Smad2 pathway, we tested
whether recombinant Activin/Nodal ligand can rescue Smad2 signal-
ling in JQ1 treated mESCs. We were unable to source or produce
active recombinant Nodal [27]; however, Activin A uses the same
TGFb receptor family as Nodal [28,29]. Accordingly, Activin A
treatment robustly restores Smad2 phosphorylation in JQ1-treated
cells, in contrast to TGFb1 or BMP4 (Fig 3D). Activin A treatment
also rescues expression of ME markers Brachyury (Fig 3E) and Mixl
(Fig EV2B) following JQ1 treatment, whilst TGFb1 and BMP4 do
not. Expression of Nodal itself is not rescued by Activin A treatment
(Fig EV2B), highlighting a specific defect in autocrine Nodal produc-
tion. These data also confirm that JQ1 does not inhibit the Trim33
bromodomain containing protein, which is required downstream of
Nodal-Smad2 for ME differentiation [27]. We therefore propose that
BET inhibitors block Smad2 signalling and PSC differentiation by
suppressing Activin/Nodal production. This mechanism is specific
to Nodal signalling, as JQ1 does not inhibit TGFb1-Smad2 dependent
PAI-1 transcription in U2OS cells [30] (Fig EV2C).
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Figure 2. BET bromodomain activity is required for Smad2 signalling and mESC differentiation.
A mESCs differentiating upon 2i release for 1.5 days were treated with 3 lM SB505124 or 100 nM JQ1 for a further 2.5 days. Smad2 Ser465/467, b-catenin Ser33/37/41
and Erk1/2 Thr202/Tyr204 phosphorylation and total Erk1/2 were determined by immunoblotting (n = 3).
B mESCs differentiating upon 2i release for 2 days were treated with the indicated inhibitor concentrations. Smad2 phosphorylation and total Smad2 were evaluated by
immunoblotting (n = 3).
C mESCs differentiating upon 2i release for 1.5 days were treated with the indicated inhibitors for a further 2.5 days. Brachyury mRNA levels were determined by qRT–
PCR and normalised to DMSO control. Data are presented as mean  SEM of technical replicates from three independent experiments (n = 3). Two-tailed unpaired
Student’s t-test; ns = not significant, ***P < 0.001 and ****P < 0.0001.
D mESCs differentiating upon 2i release for 1.5 days were treated with 3 lM SB505124 or 100 nM JQ1 for a further 2.5 days. Brachyury and Sox1 mRNA levels were
determined by qRT–PCR. Data presented as mean  SEM of technical replicates from three experiments (n = 3). Two-tailed unpaired Student’s t-test (**P < 0.01 and
****P < 0.0001).
Source data are available online for this figure.
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BET-Nodal-Smad2 signalling modulates directed differentiation
of hiPSCs to dEN
Next, we explored the wider developmental and therapeutic signifi-
cance of Nodal-Smad2 regulation by BET family bromodomains.
Specification of human-induced pluripotent stem cells (hiPSCs) to
definitive endoderm (dEN) is a key intermediate step in pancreatic
and hepatic development [2]. Differentiation of Sox17+/FoxA2+ dEN
from hiPSCs is initiated by the Wnt activator CHIR99021 followed by
Activin A treatment (Fig 4A). In this system, CHIR99021 drives Smad2
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phosphorylation and dEN differentiation [31], and this is abolished by
JQ1 treatment (Fig EV3A). Furthermore, CHIR99021 induces Nodal
expression within 6 h, which is similarly blocked by JQ1 (Fig 4B).
BET proteins are therefore required for autocrine Nodal-Smad2 signal-
ling not only in mESCs, but also in differentiating hiPSCs.
Having established the importance of BET proteins for Nodal-
Smad2 signalling in hiPSCs, we examined whether BET activity is
required for specification of hiPSCs to dEN. hiPSC treatment with
SB505124 or JQ1 suppresses Brachyury induction (Fig EV3B), indi-
cating a failure to specify ME. As a result, treatment of hiPSCs with
JQ1, even for the first 24 h of differentiation, completely abolishes
dEN specification, as assessed by dEN-specific markers FoxA2 and
Sox17 (Fig 4C) and loss of dEN morphology (Fig 4D). In contrast,
JQ1 does not significantly alter morphology of undifferentiated
hiPSC colonies (Fig 4D). Loss of dEN identity in JQ1-treated samples
is confirmed by immunostaining for FoxA2 (Fig 4E). Our data there-
fore show that BET proteins govern activation of Nodal-Smad2
signalling in hiPSCs, which plays a critical role in differentiation of
therapeutically relevant dEN progenitor cells.
Nodal gene regulatory elements (NREs) form a putative BET
protein recruitment platform
We then sought to elucidate the mechanism by which BET proteins
drive autocrine Nodal-Smad2 signalling. As key transcriptional regu-
lators, we hypothesised that BET proteins are recruited to Nodal
gene regulatory elements (NREs) to control Nodal expression. The
Nodal promoter consists of multiple NREs, including the key highly
bound element (HBE) 0.5–2.5 kb upstream [32] and the asymmetric
enhancer (ASE) 1.0 kb downstream of the transcriptional start site
(Fig EV4A). We therefore examined whether NREs contain lysine-
acetylated histone H4 BET bromodomain binding motifs [24], which
could in principle directly recruit BET family members [33]. Indeed,
chromatin immunoprecipitation (ChIP) using an anti-acetyl K5/K8/
K12/K16 histone H4 antibody enriches for the Nodal HBE
(Fig EV4B), confirming that the Nodal promoter is a potential
recruitment site for BET family bromodomain proteins.
Determining BET family expression dynamics by
quantitative proteomics
In order to determine which BET family members might be recruited
to NREs in differentiating mESCs, we conduct quantitative whole
cell proteomics to determine the relative expression of BET family
members. We quantify total protein copy number per cell from
mESCs in LIF/FCS. This analysis identified all members of the BET
family: Brd2, Brd3, Brd4, and Brdt. Brd2 (204,033  30,770 copies
per cell) and Brd4 (142,198  1,436 copies per cell) are the major
isoforms expressed in mESCs in LIF/FCS (Fig 5A), although Brd3
is also expressed at significant levels (92,437  2,483 copies per
cell). The testis-specific isoform Brdt is expressed at very low
levels in mESCs (135  17.8 copies per cell).
Brd2 and Brd4 engage NREs to modulate Nodal
gene transcription
Our finding that Brd2 and Brd4 are abundantly expressed in
mESCs (Fig 5A) prompted us to determine whether Brd2 and
◀ Figure 3. BET bromodomain function patterns autocrine Nodal expression and signalling.A Graphical representation of RNAseq data (GSE60171) corresponding to a list of TGFb-Smad2 and Wnt pathway genes. Data represent the log2 fold change in mRNA
expression of hESCs treated with MS436 BET inhibitor compared to control. Genes repressed by BET inhibition are shown in green and induced genes are in red.
B mESCs differentiating upon 2i release for 1.5 days were treated with 100 nM JQ1 for a further 2.5 days, and levels of the indicated transcripts determined by qRT–
PCR. Table shows the mean fold change in mRNA expression, with genes repressed by JQ1 in green and the induced ones in red. Data from a representative
experiment are shown. Similar results were observed in three independent experiments (n = 3).
C Relative mRNA expression of the indicated TGFb superfamily ligands determined by qRT–PCR. Data are presented as mean  SD of technical replicates. Similar
results were observed in three independent experiments (n = 3).
D mESCs differentiating upon 2i release were treated with 100 nM JQ1, 3 lM SB505124 or 1 lM LDN193189 for 2.5 days and then stimulated with Activin A, TGFb1 or
BMP4 for 30 min. Smad2 phosphorylation, total Smad2 and Lamin B1 levels were determined by immunoblotting. Data from a representative experiment are shown.
Similar results were observed in three independent experiments (n = 3).
E mESCs differentiating upon 2i release were treated with 100 nM JQ1 for 2.5 days and stimulated with TGFb1, Activin A and BMP4 for 48 h. Brachyury mRNA levels
determined by qRT–PCR. Data are presented as mean  SD of technical replicates. Statistical significance was determined for each condition relative to control using
two-tailed unpaired Student’s t-test; ns = not significant, **P < 0.01. Similar results were found in three independent experiments (n = 3).
Source data are available online for this figure.
▸Figure 4. BET-Nodal-Smad2 signalling axis modulates directed differentiation of hiPSCs to definitive endoderm.A Experimental workflow for directed differentiation of Sox17+/FoxA2+ definitive endoderm (dEN) from human-induced pluripotent stem cells (hiPSCs).
B hiPSCs treated with 3 lM CHIR99021 were co-treated with DMSO (Control), 3 lM SB505124 or 100 nM JQ1 for 24 h and RNA or protein was collected at the
indicated time points. Nodal mRNA was quantified by qRT–PCR and represented as mean  SD of technical replicates. Smad2 phosphorylation and total Smad2
protein levels were determined by immunoblotting and quantified using ImageLab software. Similar results were found in three independent experiments (n = 3).
C hiPSCs undergoing dEN differentiation were treated with SB505124 or JQ1 for either the first 24 h (“pulse”) or for the whole dEN differentiation process (“sustained”).
Levels of FoxA2 and Sox17 mRNAs were determined by qRT–PCR. Data are presented as mean  SD of technical replicates. Statistical significance was determined for
each condition relative to control using two-tailed unpaired Student’s t-test (*P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001). Similar results were found in
three independent experiments (n = 3).
D hiPSCs undergoing dEN differentiation were treated with SB505124 or JQ1 for either the first 24 h (“pulse”) or for the whole dEN differentiation process (“sustained”).
Phase contrast images were obtained at 10× objective. Similar results were found in three independent experiments (n = 3).
E hiPSCs undergoing dEN differentiation were fixed and immunostained for FoxA2 and DAPI stained to identify nuclei. Images were taken using a confocal microscope
at 10× objective. Right panel shows a zoomed in view of an area from the respective images on the left panel.
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Brd4 directly engage NREs. Brd2- and Brd4-specific chromatin
immunoprecipitation (ChIP) from differentiating mESCs enriches
all NREs examined, including the HBE (–2.0 kb), transcriptional
start site (0.0 kb) and ASE (1.0 kb), when compared to IgG
control (Fig 5B). The NRE enrichment by Brd2 and Brd4 ChIP is
highly selective, as it is abolished by MZ1-mediated degradation
of BET proteins (Fig EV4C; note that NRE enrichment by Brd4 is
significantly higher in 2i than in differentiating mESCs). MZ1 is a
proteolysis targeting chimera (PROTAC) compound which chemi-
cally tethers BET proteins to the Von Hippel Lindau (VHL) E3
ligase, thereby eliciting specific degradation of Brd4 [34,35].
Importantly, Brd2 and Brd4 ChIP does not significantly enrich a
distal genomic region reported as a low-level binder of BET
bromodomain proteins [36] (Fig EV4D).
Our data suggest that BET proteins engage NREs to directly
control Nodal gene transcription. Consistent with this notion, we
show that JQ1 suppresses transcription of nascent Nodal mRNA, in
addition to reducing steady-state levels (Fig EV4E). JQ1 also inhibits
recruitment of Cdk9, which is required for transcriptional
elongation, to the Nodal transcriptional start site (Fig 5C), suggest-
ing a molecular mechanism by which BET inhibition disrupts Nodal
transcription. In contrast, JQ1 does not alter deposition of activating
H3K4me3 marks at NREs, indicating that key epigenetic features of
the Nodal gene remain unchanged upon BET inhibition (Fig 5D).
Taken together, our data demonstrate that Brd2-4 directly control
Nodal gene expression by regulating transcriptional machinery at
NREs.
BET family isoform switching alters Brd2-4 Nodal occupancy
during mESC differentiation
Next, we sought to determine whether Brd2 and/or Brd4 are
required for Nodal-Smad2 signalling during ME specification. To
this end, we analysed expression dynamics of BET isoforms during
mESC differentiation. Relative expression of BET family members in
LIF/FCS mESCs and 2i mESCs at different stages of differentiation
was evaluated by immunoblotting whole cell extracts (Fig 5E). We
then extrapolated LIF/FCS mESC quantitative proteomics data to
◀ Figure 5. BET protein expression dynamics during mESC differentiation underpin differential engagement to Nodal regulatory regions.A Absolute abundance of BET family members (copy number/cell) was determined in mESCs cultured in LIF/FCS using quantitative whole cell proteomics. Data are
presented as mean  SD of technical replicates from three independent experiments (n = 3).
B ChIP was performed on mESCs differentiating upon 2i release using anti-Brd2- and anti-Brd4-specific antibodies or respective IgG controls. Abundance of NRE
genomic sequences was quantified by qPCR and the percentage of ChIP DNA compared to input calculated. Data are presented as mean  SEM of technical
replicates from a representative experiment. Similar results were obtained in three independent experiments (n = 3).
C ChIP was performed on mESCs differentiating upon 2i release using anti-Cdk9 antibody or IgG control following treatment with 100 nM JQ1 or DMSO for 48 h.
Abundance of NRE genomic sequences was quantified by qPCR and the percentage of ChIP DNA compared to input calculated. Data are presented as mean  SEM
of technical replicates from a representative experiment. Similar results were obtained in three independent experiments (n = 3).
D ChIP was performed on mESCs differentiating upon 2i release using anti-histone H3K4me3 antibody or IgG control following treatment with 100 nM JQ1 or DMSO for
48 h. Abundance of NRE genomic sequences was quantified by qPCR and the percentage of ChIP DNA compared to input calculated. Data are presented as
mean  SEM of technical replicates from a representative experiment. Similar results were obtained in three independent experiments (n = 3).
E Brd2, Brd3 and Brd4 protein levels were determined by immunoblotting in 2i mESCs or a time-course of mESCs differentiating upon 2i release. Low and high
exposures of Brd4(S) are provided (Lo and Hi, respectively). A non-specific band in Brd4(S) is highlighted by an asterisk (left panel). ImageLab software was used for
image acquisition and densitometric analysis, and values were compared to LIF/FCS control and proteomic data to extrapolate Brd2, Brd3 and Brd4 copy number/cell
at each time point. Graph represents the number of copies of the indicated BET protein over time (Right panel). Similar results were obtained in three independent
experiments (n = 3).
F ChIP was performed on mESCs using Brd2 and Brd4 antibodies and the respective IgG controls every day during the course of 2i release. Abundance of NRE genomic
sequences was quantified by qPCR, and the percentage of ChIP DNA over input was calculated. Data are presented as mean  SEM of technical replicates from a
representative experiment. Similar results were found in more than three independent experiments.
G ChIP was performed on 2i mESCs using anti-Brd2 antibody or IgG control following transfection with control or Brd4 siRNA. Abundance of NRE genomic sequences
was quantified by qPCR and the percentage of ChIP DNA compared to input calculated. Data are presented as mean  SEM of technical replicates from a
representative experiment. Similar results were obtained in three independent experiments (n = 3).
Source data are available online for this figure.
▸Figure 6. Specific roles for Brd4 and Brd2 in pluripotency and mesendoderm differentiation of mESCs.A 2i mESCs were transfected with control, Brd2, Brd3 or Brd4 siRNAs, and phase contrast images were taken after 48 h at 10× objective. Similar results were obtained
from three independent experiments (n = 3).
B 2i mESCs were transfected with control, Brd2, Brd3 or Brd4 siRNAs and Nanog, Brd2, Brd3, Brd4 and Lamin B1 protein levels evaluated by immunoblotting. Similar
results were obtained from three independent experiments (n = 3).
C 2i mESCs were treated with the indicated concentrations of MZ1 for 4 h and Brd4, Brd2, Nanog and Lamin B1 protein levels determined by immunoblotting. A non-
specific band in Brd4(S) is highlighted by an asterisk (left panel). Similar results were obtained from three independent experiments (n = 3).
D mESCs differentiating upon 2i release were transfected with control, Brd2, Brd3 or Brd4 siRNAs and cultured for 72 h. Nodal and Brachyury mRNA levels were
determined by qRT–PCR. Box plots show technical replicates from at least three independent experiments. Boxes extend from the 25th to the 75th percentile, with the
median represented as a line segment inside each box. The whiskers expand from the minimum to the maximum value. Statistical significance was determined for
each condition relative to control using two-tailed unpaired Student’s t-test (ns = not significant, **P < 0.01 and ***P < 0.001).
E ChIP was performed on mESCs differentiating upon 2i release using anti-Cdk9 antibody or IgG control following transfection with control or Brd2 siRNA. Abundance
of NRE genomic sequences was quantified by qPCR and the percentage of ChIP DNA compared to input calculated. Data are presented as mean  SEM of technical
replicates from a representative experiment. Similar results were obtained from three independent experiments (n = 3).
F ChIP was performed on mESCs differentiating upon 2i release using anti-histone H3K4me3 antibody or IgG control following 48 h transfection with control or Brd2
siRNA. Abundance of NRE genomic sequences was quantified by qPCR and the percentage of ChIP DNA compared to input calculated. Data are presented as
mean  SEM of technical replicates from a representative experiment. Similar results were obtained from three independent experiments (n = 3).
Source data are available online for this figure.
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determine the protein copy number per cell of Brd2, Brd3 and Brd4
short and long isoforms (Brd4 (S) and (L), respectively) in 2i and
during release by relative quantification of immunoblotting data.
This analysis indicates that Brd4 is the most abundant isoform in 2i
mESCs (~250,000 protein copies per cell), followed by Brd2
(~200,000 copies per cell; Fig 5E). However, 2i release leads to
rapid and sustained suppression of Brd4, stabilising at
~100,000 copies per cell. In contrast, Brd2 expression remains rela-
tively constant at ~200,000 copies per cell (Fig 5E).
Our results suggest that BET family expression dynamics during
mESC differentiation may reduce Brd4 bound NREs whilst increas-
ing Brd2 occupancy. To test this possibility, we compared Brd2 and
Brd4 engagement of NREs during a time-course of mESC differentia-
tion following 2i release. Strikingly, NREs are highly enriched in
Brd4 ChIP from 2i mESCs, and this is reduced in a graded fashion
during mESC differentiation (Fig 5F). In contrast, NREs are
modestly enriched in Brd2 ChIP from 2i ESCs, but Brd2 NRE occu-
pancy increases upon differentiation (Fig 5F). Our data therefore
indicate that Brd4-Brd2 “isoform switching” during mESC differenti-
ation leads to loss of Brd4 and consequent enrichment of Brd2 at
key Nodal gene regulatory elements. To directly test this, we exam-
ine Brd2 recruitment to NREs following Brd4 siRNA depletion.
Strikingly, Brd4 knockdown augments Brd2 recruitment to NREs in
2i mESCs (Fig 5G), confirming that Brd2 and Brd4 compete for
regulatory binding sites at the Nodal promoter.
Brd2 specifically promotes autocrine Nodal expression and
mesendoderm specification in differentiating mESCs
An isoform switch whereby Brd2 recruitment to NREs increases
following Brd4 downregulation could, in principle, coordinate
pluripotency exit with Nodal-Smad2 dependent mesendoderm dif-
ferentiation. This hypothesis predicts that Brd4 suppression drives
pluripotent exit [22], enabling Brd2 to become a specific and essen-
tial driver of Nodal-Smad2 signalling and ME differentiation. We
addressed this by depleting individual BET family members by
siRNA in 2i or differentiating mESCs. As predicted, knockdown of
Brd2 or Brd3 does not significantly alter 2i mESC morphology
(Fig 6A). However, Brd4 knockdown promotes a flattened
morphology characteristic of differentiating mESCs [22] (Fig 6A).
Furthermore, Brd4 knockdown in 2i mESCs potently suppresses
Nanog expression (Fig 6B) and drives induction of the neural
marker Sox1 (Fig EV5A), confirming exit from pluripotency. In
contrast, Brd2 or Brd3 knockdown have minor effects on Nanog
(Fig 6B) and Sox1 expression (Fig EV5A), confirming the specific
role of Brd4 in pluripotency maintenance [22]. We obtain similar
results using MZ1 under conditions where Brd4 is specifically
degraded (Fig 6C) [34], confirming that Nanog expression and
pluripotency maintenance are Brd4 dependent.
Our finding that BET family isoform switching occurs at NREs
during pluripotent exit implicates Brd2 as an essential driver of
Nodal-Smad2 signalling and ME differentiation. Indeed, knockdown
of Brd2, but not Brd3 or Brd4, significantly suppresses Nodal expres-
sion in differentiating mESCs (Fig 6D). Accordingly, specific knock-
down of Brd2 significantly suppresses ME differentiation, as
measured by expression of Brachyury (Fig 6D), Mixl, Lefty1 or
Lefty2 (Fig EV5B). We quantify the level of siRNA knockdown
achieved for Brd2-4 (Fig EV5C) and confirm that multiple Brd2
siRNA sequences significantly suppress Nodal and Brachyury
expression (Fig EV5D). Our data therefore argue that Brd2 is a criti-
cal regulator of Nodal transcription and signalling in differentiating
mESCs. Consistent with this notion, Brd2 is required for recruitment
of Cdk9, a key driver of transcriptional elongation, to NREs (Fig 6E).
However, Brd2 is not required for deposition of activating H3K4me3
marks at NREs, indicating that key epigenetic features of the Nodal
gene remain unaltered (Fig 6F). In summary, our results propose a
model whereby Brd4 depletion drives pluripotent exit and BET
family isoform switching at the Nodal promoter, whereupon Brd2
comes to prominence as a critical regulator of autocrine Nodal-
Smad2 signalling and ME specification (Fig 7).
Discussion
Nodal-Smad2 is a central signalling pathway in ESC/PSC biology
and plays a critical role during early development [26]. However,
the mechanisms governing activation of the Nodal-Smad2 signalling
network during development remain poorly understood. Here, we
show that BET family bromodomain proteins are specifically
required for Nodal signalling, Smad2 activation and ME differentia-
tion of pluripotent cells. Our findings speak to a general concept that
key transcriptional components such as BET bromodomains
perform highly specific functions in different biological contexts.
This notion is supported by recent work indicating that BET proteins
frequently function at lineage-specific genes [37]. Interestingly,
specific roles of BET family proteins appear to be conferred via the
differential repertoires of co-factors expressed in cells with distinct
developmental destinies.
In this study, we uncover a dynamic regulatory system, which is
critical to coordinate pluripotent exit with early lineage specification.
This is underpinned by “isoform switching” in the BET family,
whereby Brd4 downregulation extinguishes pluripotency gene expres-
sion and initiates pluripotent exit [22,25]. We show that Brd2 then
comes to prominence during differentiation, replacing Brd4 at Nodal
promoter elements to drive autocrine Nodal-Smad2 signalling
required for ME differentiation. An important facet of this switch is
that Brd4 and Brd2 display specific functional capabilities. Only Brd4
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Figure 7. Isoform switching and Brd2-4 functional dynamics
coordinate mESC exit from pluripotency with Nodal-Smad2 dependent
mesendoderm specification.
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supports Nanog expression, whereas Brd2 is able to drive Nodal
expression and ME differentiation in the absence of Brd4. This mech-
anism may be underpinned by specific functions of Brd4 at distal
enhancers [33] or super-enhancers, which are required for the expres-
sion of Nanog and other key developmental genes [38–40]. In
contrast, core promoter elements of active genes are frequently co-
occupied by Brd2, Brd3 and Brd4 together with RNAPolII and Med1
[33], which is consistent with Brd2 and Brd4 occupancy observed at
proximal NREs. Importantly, we show that Brd2 binding to proximal
NREs is required for Cdk9 recruitment and is sufficient for Nodal
expression and Smad2 signalling during PSC differentiation.
It has been reported that BET inhibition induces ESCs to differen-
tiate to neural lineages [22]. This may be explained by our finding
that BET inhibition disables Smad2 signalling in PSCs. “Dual Smad”
inhibition (referring to blockade of both TGFb and BMP signalling
pathways) is frequently used to efficiently differentiate neurons
in vitro [41]. Furthermore, the BET bromodomain inhibitor IBET-
151 forms part of a cocktail of small molecules used to directly
convert fibroblasts to neurons [42]. Interestingly, IBET-151 func-
tions by suppressing expression of fibroblast-specific genes, which
may reflect loss of fibroblast identity upon Smad2 inhibition. Our
data suggest that BET inhibition represents an effective strategy to
disrupt Activin/Nodal signalling during neural differentiation, as
this approach blocks ligand production and signal initiation, rather
than inhibiting receptors or Smad2 directly, which may be rather
less efficient and/or short-lived.
Finally, our results imply that BET bromodomains may control
Smad2 signalling in disease contexts. Nodal overexpression is asso-
ciated with epithelial to mesenchymal transition and invasiveness in
certain cancers [43], suggesting that disease pathologies caused by
deregulated Activin/Nodal might be reversed by BET inhibition.
BET inhibitors could be readily exploited in this therapeutic setting,
as they are already approved for treatment of cancers where onco-
gene expression (e.g. c-Myc) displays a strong dependency upon
Brd4 [44].
Materials and Methods
Cell culture and differentiation
CGR8 mouse embryonic stem cells (ESCs) were maintained in 2i
medium, DMEM/F12-Neurobasal (1:1), 0.5% N2, 1% B27 (Thermo-
Fisher Scientific), 1% L-glutamine, 100 lM b-mercaptoethanol,
3 lM CHIR99021 and 1 lM PD0325901. To induce differentiation,
cells were plated at 4 × 104 cells/cm2 in “2i release” medium (2i
medium without CHIR99021 and PD0325901). Human-induced
pluripotent stem cells (hiPSCs) were maintained in DEF-CS (Cellartis
AB) and seeded on matrigel (10 lg/cm2) in DEF-CS for 3–4 days. To
induce dEN differentiation, medium was changed to RPMI contain-
ing 25 mM HEPES and 3 lM CHIR99021 for 24 h, then replaced by
RPMI-1640/Activin A (25 ng/ml) for 24 h prior to culture in RPMI/
1x B27/Activin A (25 ng/ml) for 2 days.
Small molecule screen
2i mESCs were plated at 8 × 104 cells in 24-well plates and differen-
tiated in 2i release medium for 1.5 days. Media was then replaced
by fresh media containing inhibitors or DMSO control and cells
grown for a further 2.5 days prior to lysis, RNA extraction and
quantitative RT–PCR (qPCR) analysis as described below.
Immunoblotting
Cells were washed with phosphate-buffered saline (PBS) and lysed
in ice-cold lysis buffer [20 mM Tris–HCl pH7.4, 150 mM NaCl, 1mM
EDTA, 1% NP-40, 0.5% Na deoxycholate, 10 mM b-Glyceropho-
sphate, 50 mM NaF, 10 mM NaPPi, 2 mM Na orthovanadate, 10%
glycerol and complete protease inhibitor tablets (Roche)]. Protein
extracts were quantified by BCA assay, and equal amounts of
protein (10–30 lg) were subjected to SDS/PAGE, transferred to
PVDF membranes and immunoblotted (see Appendix Table S2).
Immunofluorescence and microscopy
hiPSCs were fixed in 4% (v/v) formaldehyde in PBS at room
temperature for 10 min, washed twice with PBS, post-fixed with ice-
cold 90% methanol for 5 min at –20°C, washed with PBS twice and
blocked in 4% BSA in Tris-buffered saline with 0.1% Tween-20
(TBS-T) at room temperature for 1 h. Cells were incubated in
primary antibody at 4°C overnight. After three washes with TBS-T,
secondary antibody (Life Technologies) was added and incubated at
room temperature for 1 h. After three washes with TBS-T, DAPI was
added as a nuclear counterstain. Images were taken using a confocal
microscope (Zeiss LSM 700).
RNA extraction and qRT–PCR
RNA was extracted using the OMEGA total RNA kit and reverse
transcribed using iScript reverse transcriptase (Bio-Rad) according
to the manufacturer’s instructions. qPCR was then performed using
SsoFastTM EvaGreen Supermix (Bio-Rad). See Appendix Table S3
for a list of primers. DCt values using GAPDH as a reference gene
were used to analyse the relative expression, and the 2DDCt (Livak)
method was used to normalise to control when required.
Proteomic quantification of BET proteins
Sample preparation and TMT labelling
Cell pellets were lysed in 400 ll lysis buffer (4% SDS, 50 mM TEAB
pH 8.5, 10 mM TCEP), boiled and sonicated with a BioRuptor (30
cycles: 30 s on, 30 s off) before alkylation with iodoacetamide for 1 h
at room temperature in the dark. Lysates were subjected to the SP3
procedure for protein clean-up [45] before elution into digest buffer
(0.1% SDS, 50 mM TEAB pH 8.5, 1 mM CaCl2) and digest with LysC
and Trypsin at a 1:50 (enzyme:protein) ratio. TMT labelling and
peptide clean-up were performed according to the SP3 protocol.
Samples were eluted into 2% DMSO, combined and dried in vacuo.
Basic reverse-phase fractionation
TMT samples were fractionated using offline high pH reverse-phase
chromatography: samples were loaded onto a 4.6 × 250 mm
XbridgeTM BEH130 C18 column with 3.5 lm particles (Waters).
Using a Dionex BioRS system, the samples were separated using a
25-min multistep gradient of solvents A (10 mM formate at pH 9 in
2% acetonitrile) and B (10 mM ammonium formate pH 9 in 80%
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acetonitrile), at a flow rate of 1 ml/min. Peptides were separated
into 48 fractions, consolidated into 24, dried and peptides redis-
solved in 5% formic acid and analysed by LC-MS.
Liquid chromatography electrospray tandem mass spectrometry
analysis (LC-ES-MS/MS)
1 lg of protein per fraction was analysed using an Orbitrap
Fusion Tribrid mass spectrometer (Thermo Scientific) equipped
with a Dionex ultra high-pressure liquid chromatography system
(nano RSLC). RP-LC was performed using a Dionex RSLC nano
HPLC (Thermo Scientific). Peptides were injected onto a
75 lm × 2 cm PepMap-C18 pre-column and resolved on a
75 lm × 50 cm RP-C18 EASY-Spray temperature controlled inte-
grated column-emitter (Thermo) using a 4-h multistep gradient
from 5% B to 35% B with a constant flow of 200 nl/min. The
mobile phases were: 2% ACN incorporating 0.1% FA (Solvent A)
and 80% ACN incorporating 0.1% FA (Solvent B). The spray was
initiated by applying 2.5 kV to the EASY-Spray emitter, and the
data were acquired under the control of Xcalibur software in a
data-dependent mode using top speed and 4 s duration per cycle,
the survey scan is acquired in the Orbitrap covering the m/z
range from 400 to 1,400 Th with a mass resolution of 120,000
and an automatic gain control (AGC) target of 2.0 e5 ions. The
most intense ions were selected for fragmentation using CID in
the ion trap with 30% CID collision energy and an isolation
window of 1.6 Th. The AGC target was set to 1.0 e4 with a maxi-
mum injection time of 70 ms and a dynamic exclusion of 80 s.
During the MS3 analysis for more accurate TMT quantifications,
10 fragment ions were co-isolated using synchronous precursor
selection using a window of 2 Th and further fragmented using
HCD collision energy of 55%. The fragments were then analysed
in the Orbitrap with a resolution of 60,000. The AGC target was
set to 1.0 e5, and the maximum injection time was set to
300 ms.
Database searching and reporter ion quantification
The data were processed, searched and quantified with the
MaxQuant software package, version 1.5.3.30. Proteins and
peptides were identified using the UniProt mouse reference
proteome database (SwissProt and Trembl accessed on 24.03.2016)
and the contaminants database integrated in MaxQuant using the
Andromeda search engine [46,47] with the following search
parameters: carbamidomethylation of cysteine and TMT modifi-
cation on peptide N-termini and lysine side chains were fixed
modifications, whilst methionine oxidation, acetylation of
N-termini of proteins, conversion of glutamine to pyro-glutamate
and phosphorylation on STY were variable modifications. The false
discovery rate was set to 1% for positive identification of proteins
and peptides with the help of the reversed mouse Uniprot database
in a decoy approach. Copy numbers of BET proteins were calcu-
lated as described [48] after allocating the summed MS1 intensities
to the different experimental conditions according to their frac-
tional MS3 reporter intensities.
siRNA silencing
mESCs were transfected with 30 nM ON-TARGET plus SMART-pool
or two individual sequences for either Brd2, Brd3 or Brd4, and with
the SMART-pool non-targeting control siRNA (Dharmacon) using
Lipofectamine RNAimax (Invitrogen) following the manufacturer’s
instructions. RNA or protein were extracted after 72 h for further
analyses.
Chromatin immunoprecipitation
Cells were cultured as described above and treated with 1 lM MZ1
[34] for 3 h where indicated. Crosslinking was performed by 1%
(w/v) formaldehyde treatment for 10 min at room temperature and
terminated by addition of 0.125 M glycine. Cells were washed with
PBS twice and lysed in 50 mM Tris/HCl (pH 8.1), 10 mM EDTA,
complete protease inhibitor cocktail (Roche) and 1% (w/v) SDS.
Chromatin was sheared by fifteen 30-s pulses (30 s pause between
pulses) at 4°C in a waterbath sonicator (Bioruptor, Diagenode).
Soluble whole cell extract was diluted 10-fold in 20 mM Tris/HCl
(pH 8.1), 2 mM EDTA, 150 mM NaCl and 1% (v/v) Triton X-100,
and pre-cleared for 2 h at 4°C with 20 ll either protein A-agarose
(rabbit antibodies) or protein G-agarose (sheep antibodies) beads
and 2 lg of sheared salmon sperm DNA. Sample was incubated
overnight at 4°C with 5 lg of the appropriate antibodies or 5 lg of
control IgG, then for 1 h at 4°C on a rotating platform with 30 ll of
either protein A-agarose (rabbit antibodies) or protein G-agarose
(sheep antibodies). Beads were washed in wash buffer 1 (20 mM
Tris/HCl (pH 8.0), 2 mM EDTA, 150 mM NaCl, 0.1% SDS and 1%
(v/v) Triton X-100), wash buffer 2 (20 mM Tris/HCl (pH 8.0),
2 mM EDTA, 500 mM NaCl, 0.1% SDS and 1% (v/v) Triton X-100)
then wash buffer 3 (10 mM Tris/HCl (pH 8.0), 1 mM EDTA, 0.25 M
LiCl, 1% (v/v) Nonidet P40 and 1% (w/v) sodium deoxycholate),
and twice with TE (10 mM Tris/HCl pH 8.0 and 1 mM EDTA).
Bound complexes were eluted from the beads with 0.1 M NaHCO3
and 1% (w/v) SDS, and crosslinking reversed by overnight incuba-
tion at 65°C in 0.2 M NaCl. Whole cell extracts were also subjected
to crosslinking reversal. All samples were then incubated with
RNase for 1 h and proteinase K (Roche) for 1 h at 45°C, and purified
by Spin Column PCR purification kit (NBS Bio). Purified immuno-
precipitated DNA and input DNA were analysed by qPCR using the
SsoFast
TM EvaGreen Supermix. See Appendix Table S4 for primers
used for amplification.
Statistics
Graphical data were generated and analysed by GraphPad PRISM
software. Statistical analyses were performed using unpaired
2-tailed Student’s t-test.
Materials
The following reagents generated for this study are available to
request through the MRC-PPU reagents website (https://mrcppurea
gents.dundee.ac.uk/): Small molecule inhibitor collection and Brd4
ChIP antibody.
Data availability
Gene Expression Omnibus GSE60171 [22].
Expanded View for this article is available online.
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